Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, tofacitinib monotherapy was effective in achieving hair regrowth in over half of Korean patients with moderate-to-severe and refractory alopecia areata, though treatment discontinuation typically led to hair loss recurrence.

This case report highlights a 33-year-old female with systemic lupus erythematosus and refractory alopecia who experienced significant hair regrowth after treatment with tofacitinib, maintained even after glucocorticoid tapering over two years.

In this study, researchers identified a unique variant of alopecia areata characterized by an increase in telogen hair follicles and minimal inflammation present in the microenvironment.

In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.

This review summarizes current treatments for recalcitrant alopecia areata and recent therapeutic developments targeting specific immunological pathways, reporting no new clinical results.

In this case study, a Pomeranian was diagnosed with vaccine-induced ischemic dermatopathy, where different medication regimens gradually improved hair regrowth, though some lesions persisted after tapering treatment.

This study found that exosome injections from human umbilical cord, with or without polydeoxyribonucleotide, promoted regrowth and repigmentation of white beard hairs and improved scarring in a 35-year-old man with refractory alopecia areata, suggesting potential as a minimally invasive regenerative treatment.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

This article discusses the progression, treatment options, and support resources for individuals with alopecia areata, but reports no new clinical results.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

In this case report, significant improvements in a 58-year-old male with severe refractory myasthenia gravis and concurrent alopecia areata were observed following a cortisone taper, suggesting a potential therapeutic role, especially after thymectomy.

This study presents the first documented case of dramatic hair regrowth in a systemic lupus erythematosus patient with refractory alopecia following tofacitinib therapy, suggesting a potential new application for JAK inhibitors in difficult-to-treat cutaneous SLE manifestations.

In this report, two young patients with corticosteroid-refractory alopecia totalis experienced safety and efficacy from oral tacrolimus.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

In this case report, a patient with severe erythrodermic psoriasis and diffuse alopecia who was unresponsive to conventional treatments showed complete resolution of skin lesions and alopecia after being treated with ixekizumab.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

This article reviews characteristics and mental health impacts of alopecia areata but provides no new clinical findings; future research is encouraged.

This study reported improvement in an 11-year-old boy with refractory alopecia areata after 4 months of treatment with oral abrocitinib, a JAK1 inhibitor, suggesting it may be a potential alternative for pediatric patients unresponsive to conventional therapies.

In this case study, a 39-year-old Japanese woman with severe alopecia areata demonstrated complete hair regrowth after one year using a combination of 0.5% delgocitinib ointment and excimer laser, suggesting potential efficacy and safety compared to conventional treatments.

This article reviews treatment options and considerations for alopecia areata, including progression, prognosis, and support resources, but reports no new clinical findings.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

The exosome injections were from stem cells and plants, not umbilical cords.

This study reports a case where treatment with the TNF alpha inhibitor infliximab successfully resolved refractory alopecia universalis in a 41-year-old woman.

This study observed that nearly 70% of children with treatment-resistant alopecia areata had nail involvement, primarily pitting, and this was significantly associated with longer disease duration but not disease severity.

The study suggests that refractory chronic alopecia areata cases have more infiltrating skin resident memory T cells, and using a JAK inhibitor may be an effective treatment option.

In this case series, four African American women with treatment-resistant central centrifugal cicatricial alopecia showed scalp itch relief and significant hair regrowth after using a new botanical formula for 8 weeks to 1 year, with no adverse effects reported.

This study reports that oral tofacitinib treatment in a patient with refractory lichen planus pigmentosus and frontal fibrosing alopecia resulted in near-complete resolution of hyperpigmentation and cessation of hairline recession over 18 months, and suggests it may be a promising therapy for these challenging conditions.

In this case report, a nine-year-old child with vitiligo and alopecia areata was successfully treated with upadacitinib and UVB, resulting in a significant reduction in the affected areas, suggesting a promising treatment approach for similar pediatric cases.

This study found that intramuscular triamcinolone acetonide may be an effective and safe treatment option for managing refractory alopecia areata, showing a 63% response rate in patients and hair regrowth negatively correlated with initial scalp involvement.